Pharmaceutical Cocrystals: Formulation Approaches to Develop Robust Drug Products

被引:39
作者
Duggirala, Naga Kiran [2 ]
LaCasse, Shawn M. [1 ]
Zaworotko, Michael J. [2 ]
Krzyzaniak, Joseph F. [1 ]
Arora, Kapildev K. [1 ]
机构
[1] Pfizer Worldwide Res & Dev, Groton, CT 06340 USA
[2] Univ Limerick, Limerick, Ireland
关键词
SALT DISPROPORTIONATION; DISSOCIATION; STABILITY; SOLUBILITY; WATER; ATORVASTATIN; IONIZATION; EXCIPIENTS; CANDIDATE; SCIENCE;
D O I
10.1021/acs.cgd.9b00946
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Phase transformation of an active pharmaceutical ingredient in the solid state can influence the physicochemical properties and consequently drug product performance. The neat cocrystal of Ertugliflozin L-pyroglutamic acid (ERTLPG), trade name Steglatro, though stable at high temperature and humidity conditions, dissociated into the amorphous free form of ertugliflozin in the presence of excipients. The influence of the physicochemical properties of excipients on the physical stability of the cocrystal was investigated to gain a mechanistic understanding of cocrystal dissociation in tablet formulations. The test tablet formulations containing cocrystal and excipient(s) were prepared and stored at stressed conditions. Note that cocrystal dissociation was observed at these conditions in the presence of excipients. An FT-Raman spectroscopy method in combination with a partial least-squares (PLS) regression model was utilized to evaluate the cocrystal dissociation. To evaluate the effect of excipients on cocrystal dissociation, a binary excipient compatibility study was conducted. Excipients used for a binary formulations study were categorized into four classes based on their physicochemical properties as a function of the physical stability of the cocrystal in the binary tablet/powder formulations. The results revealed that there is a good correlation between excipient properties (at least pH and hygroscopicity) and cocrystal dissociation in the formulations. Finally, to mitigate cocrystal dissociation in sold oral dosage forms, i.e., tablets, research tablet formulations that contained cocrystal particles coated with hydrophobic silica and a pH modifier were prepared and stored at accelerated stability conditions (40 degrees C/75% RH) for up to 4 weeks. The research tablet formulations demonstrated improved physical stability of the cocrystal at accelerated conditions. The present study suggests that, in general, there is a propensity of basic excipients to induce cocrystal dissociation that contain acidic coformers during drug product manufacturing and storage. Our findings from the current study demonstrated an in-depth mechanistic understanding of factors influencing cocrystal dissociation and mitigation strategies that will aid to develop robust solid oral dosage forms.
引用
收藏
页码:617 / 626
页数:10
相关论文
共 46 条
  • [1] THE MOLECULAR-BASIS OF MOISTURE EFFECTS ON THE PHYSICAL AND CHEMICAL-STABILITY OF DRUGS IN THE SOLID-STATE
    AHLNECK, C
    ZOGRAFI, G
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 62 (2-3) : 87 - 95
  • [2] Almarsson Ö, 2012, PHARM PAT ANAL, V1, P313, DOI [10.4155/PPA.12.29, 10.4155/ppa.12.29]
  • [3] [Anonymous], Patent, Patent No. [US9,573,959B2, 9573959]
  • [4] Arora K.K., 2009, Polymorphism in Pharmaceutical Solids, V2, P281
  • [5] Instability in Theophylline and Carbamazepine Hydrate Tablets: Cocrystal Formation Due to Release of Lattice Water
    Arora, Kapildev K.
    Thakral, Seema
    Suryanarayanan, Raj
    [J]. PHARMACEUTICAL RESEARCH, 2013, 30 (07) : 1779 - 1789
  • [6] Unintended Water Mediated Cocrystal Formation in Carbamazepine and Aspirin Tablets
    Arora, Kapildev K.
    Tayade, Nitin G.
    Suryanarayanan, Raj
    [J]. MOLECULAR PHARMACEUTICS, 2011, 8 (03) : 982 - 989
  • [7] Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin
    Bernhardson, David
    Brandt, Thomas A.
    Hulford, Catherine A.
    Lehner, Richard S.
    Preston, Brian R.
    Price, Kristin
    Sagal, John F.
    St Pierre, Michael J.
    Thompson, Peter H.
    Thuma, Benjamin
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2014, 18 (01) : 57 - 65
  • [8] Mitigating Cocrystal Physical Stability Liabilities in Preclinical Formulations
    Bhardwaj, Sunny
    Lipert, Maya
    Bak, Annette
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (01) : 31 - 38
  • [9] Pharmaceutical cocrystals: walking the talk
    Bolla, Geetha
    Nangia, Ashwini
    [J]. CHEMICAL COMMUNICATIONS, 2016, 52 (54) : 8342 - 8360
  • [10] Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin
    Bowles, Paul
    Brenek, Steven J.
    Caron, Stephane
    Do, Nga M.
    Drexler, Michele T.
    Duan, Shengquan
    Dube, Pascal
    Hansen, Eric C.
    Jones, Brian P.
    Jones, Kris N.
    Ljubicic, Tomislav A.
    Makowski, Teresa W.
    Mustakis, Jason
    Nelson, Jade D.
    Olivier, Mark
    Peng, Zhihui
    Perfect, Handi H.
    Place, David W.
    Ragan, John A.
    Salisbury, John J.
    Stanchina, Corey L.
    Vanderplas, Brian C.
    Webster, Mark E.
    Weekly, R. Matt
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2014, 18 (01) : 66 - 81